Lipophilic daunorubicin prodrug - liposomal
Alternative Names: Daunorubicin lipophilic liposomal; Liposomal daunorubicin prodrugLatest Information Update: 24 Oct 2021
At a glance
- Originator Nonindustrial source
- Class Anthracyclines; Antineoplastics; Cytostatic antibiotics; Small molecules
- Mechanism of Action RNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 21 May 1999 New profile
- 21 May 1999 Preclinical development for Cancer in Netherlands (Unknown route)